In the U.S., it is estimated there will be approximately 72,680 new cases of head and neck cancer diagnosed and more than 16,680 deaths from the disease in 2025, Merck said.
Martin Kulldorff, appointed by RFK Jr. to a federal vaccine panel, previously earned $33K as an expert witness in lawsuits targeting Merck's Gardasil vaccine.
MERCK & CO. INC. (NYSE:MRK) is a value stock with strong profitability, a healthy balance sheet, and an attractive dividend. Trading below industry valuations, it may appeal to long-term investors.
Dean Y. Li, president of Merck Research Laboratories, said that the company is working with urgency to make the oral therapy available to patients worldwide.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.
